Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Sumitomo Dainippon

This page shows the latest Sumitomo Dainippon news and features for those working in and with pharma, biotech and healthcare.

BMS links up with Exscientia for $1.2bn AI drug discovery deal

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Aside from its collaboration with BMS, Exscientia has a number of additional collaborations in place with other pharma companies, including Bayer, Sanofi and Dainippon Sumitomo.

Latest news

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • A snapshot of… Exscientia A snapshot of… Exscientia

    We have so far discovered four preclinical drug candidates, and recently announced the first drug designed by AI in partnership with Sumitomo Dainippon Pharma to enter human trials.

  • The good, the bad and the ugly The good, the bad and the ugly

    2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo Dainippon Pharma (25%), with growth ... However, the imminent US patent expiry of Sumitomo

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML. ... Tolero Pharmaceuticals. Dainippon Sumitomo. $780m. Upfront payment of $200m.

  • Deal Watch August 2016 Deal Watch August 2016

    If apomorphine is the only product, the acquisition of the company by Sunovion (the US subsidiary of Dainippon Sumitomo) for $645m, paying a hefty 123% share price premium, looks very expensive ... 645. Cynapsys (CA). Sunovion (US) (Dainippon Sumitomo).

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Edison Pharmaceuticals/ Dainippon Sumitomo Pharma. Strategic alliance. Extends development/ commercialisation agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Civitas appoints Mark Iwicki as CEO Civitas appoints Mark Iwicki as CEO

    Sunovion was created after the acquisition of Iwicki's former company Sepracor by Dainippon Sumitomo Pharmaceuticals.

  • Boston Biomedical appoints commercial head Boston Biomedical appoints commercial head

    Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...

Quick links